Annovis Bio, Inc. (ANVS)
ANVSNYSEBiotechnology: Pharmaceutical Preparations
$0.8280
-0.0410 (-4.72%) today
Regular session, Nov 11, 9:48 AM ET
- Market cap
- $53.00m
- P/E
- –
- EPS, last 4 quarters
- $-1.79
- Dividend yield
- –
- Day range
- $0.8100 to $0.8400
- 52-week range
- $0.6161 to $5.50
- Average volume
- 616.6k
- Previous close
- $0.8690
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $10.67, +1188.6% from here
Earnings
next estimate $-0.3000Next report
Sep 2025
-2.8%
Dec 2025
–
Mar 2026
–
Jun 2026
+9.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.43m | -$9.71m | -$18.01m | -$14.38m |
| Net income | -$7.26m | -$9.83m | -$17.61m | -$14.82m |
News
8 latest- Annovis Closes $21 Million Offering, Funds Operations Through Phase 3 Alzheimer's Readout; Stock Up RTTNews · 2 days ago
- Annovis Bio, Inc. Reports Preliminary Cash and Cash Equivalents of approximately $2.8 millionFintel · 6 days ago
- Annovis Bio, Inc. Stockholders Approve Increase in Authorized Shares to 140,000,000Fintel · 7 days ago
- Annovis Gets NYSE Listing Notice; Plans To Regain Compliance RTTNews · Nov 2, 2026
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study RTTNews · Sep 25, 2026
- Annovis Collaborates With Weave Bio On AI Use In NDA Submission For Butanetap RTTNews · Sep 23, 2026
- Annovis Bio Consensus Price Target Lowered by 16.67% to $10.71Fintel · Sep 14, 2026
- Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · Sep 8, 2026
The company
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- annovisbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.